Last reviewed · How we verify
anlotinib combined with benmelstobart
anlotinib combined with benmelstobart is a Multi-targeted tyrosine kinase inhibitor combined with PD-L1 inhibitor Small molecule drug developed by The First Affiliated Hospital of Zhengzhou University. It is currently in Phase 3 development for Advanced or metastatic non-small cell lung cancer (Phase 3 trial indication).
Anlotinib is a multi-targeted tyrosine kinase inhibitor combined with benmelstobart (an anti-PD-L1 monoclonal antibody) to block tumor angiogenesis and enhance anti-tumor immune response.
Anlotinib is a multi-targeted tyrosine kinase inhibitor combined with benmelstobart (an anti-PD-L1 monoclonal antibody) to block tumor angiogenesis and enhance anti-tumor immune response. Used for Advanced or metastatic non-small cell lung cancer (Phase 3 trial indication).
At a glance
| Generic name | anlotinib combined with benmelstobart |
|---|---|
| Sponsor | The First Affiliated Hospital of Zhengzhou University |
| Drug class | Multi-targeted tyrosine kinase inhibitor combined with PD-L1 inhibitor |
| Target | VEGFR, FGFR, PDGFR, c-Kit (anlotinib); PD-L1 (benmelstobart) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Anlotinib inhibits multiple receptor tyrosine kinases (VEGFR, FGFR, PDGFR, c-Kit) to suppress tumor neovascularization and growth. Benmelstobart blocks the PD-L1/PD-1 checkpoint interaction, releasing T-cell inhibition and promoting anti-tumor immunity. The combination leverages both anti-angiogenic and immunotherapeutic mechanisms.
Approved indications
- Advanced or metastatic non-small cell lung cancer (Phase 3 trial indication)
Common side effects
- Hypertension
- Fatigue
- Diarrhea
- Immune-related adverse events (pneumonitis, hepatitis)
- Hand-foot skin reaction
Key clinical trials
- Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2)
- Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
- A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma (PHASE3)
- Anlotinib and Benmelstobart in DTC (PHASE2)
- Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients (PHASE2)
- Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC (PHASE2)
- Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03) (PHASE2)
- Benmelstobart-Anlotinib-Chemo for Neoadjuvant Oral Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anlotinib combined with benmelstobart CI brief — competitive landscape report
- anlotinib combined with benmelstobart updates RSS · CI watch RSS
- The First Affiliated Hospital of Zhengzhou University portfolio CI
Frequently asked questions about anlotinib combined with benmelstobart
What is anlotinib combined with benmelstobart?
How does anlotinib combined with benmelstobart work?
What is anlotinib combined with benmelstobart used for?
Who makes anlotinib combined with benmelstobart?
What drug class is anlotinib combined with benmelstobart in?
What development phase is anlotinib combined with benmelstobart in?
What are the side effects of anlotinib combined with benmelstobart?
What does anlotinib combined with benmelstobart target?
Related
- Drug class: All Multi-targeted tyrosine kinase inhibitor combined with PD-L1 inhibitor drugs
- Target: All drugs targeting VEGFR, FGFR, PDGFR, c-Kit (anlotinib); PD-L1 (benmelstobart)
- Manufacturer: The First Affiliated Hospital of Zhengzhou University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Advanced or metastatic non-small cell lung cancer (Phase 3 trial indication)
- Compare: anlotinib combined with benmelstobart vs similar drugs
- Pricing: anlotinib combined with benmelstobart cost, discount & access